External use Chinese medicine powder for treating diabetic foot ulcer

Abstract

The present invention discloses a compound Chinese medicine preparation, specifically a Chinese medicine powder for external use for treating diabetic foot ulcers. The powder is characterized in that it is prepared from the following raw materials in percentage by weight: 12-14% of whole scorpion, 12-14% of angelica, 12-14% of white ampel, 12-14% of red peony root, 7-9% of rhubarb, 7-9% of angelica dahurica, 7-9% of frankincense, 7-9% of myrrh, 7-9% of catechu, and 7-9% of dragon's blood. The Chinese medicine powder for external use can significantly treat diabetic foot ulcers by inhibiting inflammatory reactions and promoting angiogenesis.

Description

Field of the Invention

[0001] The present invention relates to the field of traditional Chinese medicine preparations, and in particular to a traditional Chinese medicine powder for external use using plants as raw materials. Background Art

[0002] Diabetic foot (DF) is a serious complication of diabetes, encompassing lower limb neuropathy and vascular disease, leading to destruction of the skin and subcutaneous tissue beyond the ankle joint. This is often accompanied by varying degrees of infection, exacerbating local tissue necrosis and ultimately causing a persistent, difficult-to-heal diabetic foot ulcer (DFU). The annual mortality rate for patients with DFUs is as high as 11%, and the rate of amputation is as high as 22%. High medical costs place a heavy burden on families and society. Peripheral neuropathy, lower limb arterial disease, and foot deformities are the primary causes of the increased risk of DFUs. The high global incidence, mortality, and financial costs make DFU a formidable challenge for the medical community.

[0003] Currently, Western medicine treatments for DFUs primarily include anti-infection, circulation improvement, surgery, local debridement, and stem cell transplantation. While these can alleviate clinical symptoms, they offer poor long-term efficacy and can lead to risks such as multidrug resistance and post-ulcer recurrence. Modern Western medicine currently lacks effective treatments for these conditions, prompting a shift in focus to traditional Chinese medicine.

[0004] Traditional Chinese Medicine (TCM) treatment of diabetic foot ulcers emphasizes combining syndrome differentiation and treatment with a holistic approach. Modern TCM classifies diabetic foot ulcers as "gangrene" based on their clinical manifestations. The "Shengji Zonglu Xiaokemen" states: "If diabetes is left untreated... the meridians become blocked, stagnating in the muscles and developing into carbuncles." This suggests that blood stasis, obstructed meridians, and malnutrition of the limbs are the primary causes of carbuncles. TCM treatment of diabetic foot ulcers not only improves TCM symptoms but also accelerates wound healing while reducing wound recurrence. This, to a certain extent, delays further deterioration of diabetic foot ulcers and reduces their disability and mortality rates. With the continuous deepening of modern medicine's research on traditional Chinese medicine, regulating cytokines with Chinese medicine monomers and compounds to treat diabetic foot ulcers has become a research hotspot. Studies have shown that sesamol, gardenia glycoside, Danggui Buxue Decoction, Zizhu Ointment, etc. regulate inflammatory factors and inhibit wound inflammation. However, these drugs still have disadvantages such as single efficacy, complex production procedures, and long treatment courses. Chinese medicine powders are easy to administer and simple to prepare. They are easy to disperse and absorb when applied externally to wounds, and they take effect quickly. In addition, external application has a certain mechanical protective effect on the wound surface.

[0005] Patent application publication number CN 109316555A discloses an external Chinese medicinal preparation that promotes the healing of chronic skin ulcer wounds. The external Chinese medicinal preparation is made from 23 Chinese medicinal materials: angelica sinensis, frankincense, myrrh, dragon's blood, safflower, earthworm, raw rehmannia, red peony root, Scrophularia ningpoensis, rhubarb, lithospermum officinale, sophora flavescens, phellodendron amurense, angelica dahurica, notopterygium wilfordii, angelica pubescens, white ampelopsis, cochinchinensis, forsythia suspensa, cinnamon bark, lindera striata, borneol, and bletilla striata. The above patent application also discloses the following content, "The present invention selects angelica, frankincense, myrrh, blood clotting, safflower, and earthworm to promote blood circulation, dredge meridians and relieve pain as the main medicine, raw rehmannia, red peony root, Scrophularia, rhubarb, and lithospermum to cool blood, relieve pain and detoxify as the auxiliary medicine, which strengthen the analgesic effect of the main medicine, sophora flavescens and phellodendron clear away heat and dampness, white angelica, notopterygium root, and duhuo have the effect of dispelling wind and dampness, and their combined effect can eliminate the damp-heat and fire toxins formed by blood stasis, poor circulation of qi and blood, and overflow outside the vessels, which accumulate under the skin to form lumps, and supplemented with white mulberry, cochinchinensis, and forsythia to clear away heat, disperse stagnation and reduce swelling. The above medicines are collectively adjuvants, official cinnamon, lindera strychnifolia, and borneol to promote menstruation and relieve pain, strengthening the analgesic effect of the main medicine, and white hyacinth to reduce swelling and promote tissue regeneration, which are collectively the guiding medicine." It has a good effect on chronic skin ulcer wounds and can effectively treat patients with relatively small ulcer surfaces and mild diabetic foot ulcers without serious infection symptoms. Although the patent application claims, "After treatment and follow-up of multiple patients with diabetic foot gangrene and decubitus ulcers, the total effective rate was 100%," the inventors believe this claim is exaggerated. First, the main ingredients, including "Danggui, Frankincense, Myrrh, Sanguisorba Officinalis, Carthamus tinctorius, and Earthworm," "are dispersed, affecting efficacy" (Li Ji and Lian Jianwei, eds., Prescriptions, China Traditional Chinese Medicine Press, 4th edition, August 2016, p. 17). Second, the efficacy study consisted of only 10 typical cases, i.e., individual cases, rather than clinical statistical reports, which cannot prove the "total effective rate is 100%." Summary of the Invention

[0006] The technical problem to be solved by the present invention is to provide an external-use Chinese medicinal powder for treating diabetic foot ulcers, which has a significant effect in treating diabetic foot ulcers.

[0007] The technical solution of the present invention to solve the above problems is:

[0008] A Chinese medicinal powder for external use for treating diabetic foot ulcers, characterized in that the Chinese medicinal powder for external use is prepared from the following raw materials in the following weight percentages:

[0009] Scorpion 12-14%, Chinese angelica 12-14%, white mulberry 12-14%, red peony root 12-14%, rhubarb 7-9%, white angelica 7-9%, frankincense 7-9%, myrrh 7-9%, catechu 7-9%, dragon's blood 7-9%.

[0010] In the above scheme of the present invention, the optimal ratio of the raw materials is: 13% of whole scorpion, 13% of angelica, 13% of white ampelopsis, 13% of red peony root, 8% of rhubarb, 8% of angelica dahurica, 8% of frankincense, 8% of myrrh, 8% of catechu, and 8% of dragon's blood.

[0011] In the above scheme, the preparation method of the external-use Chinese medicine powder is as follows:

[0012] The raw materials are ground according to the ratio, passed through a 120-mesh sieve, and prepared into the external Chinese medicine powder.

[0013] The external Chinese medicine powder of the present invention is prepared from ten Chinese medicinal herbs including scorpion, angelica, white peony root, red peony root, rhubarb, angelica dahurica, frankincense, myrrh, catechu and dragon's blood. Among them, white peony root is heat-clearing and detoxicating, and can heal sores, promote tissue regeneration and close wounds, and is the main herb; catechu is tissue regeneration and relieves pain, and can activate blood circulation, absorb dampness and heal sores; dragon's blood is invigorating and detumescence, and can heal sores and promote tissue regeneration; angelica nourishes blood and invigorates blood circulation and is the ministerial herb; red peony root is invigorating and promoting tissue regeneration, and rhubarb, frankincense and myrrh are the adjuvant herb that can activate blood circulation and promote blood circulation, reduce swelling, dissipate blood stasis and relieve pain. Scorpion and angelica dahurica are wind-clearing, meridian-dredging and detoxifying, and all the herbs in the prescription are used together to achieve the effects of removing blood stasis, detoxifying, reducing swelling and heal wounds.

[0014] The main factors affecting the prolonged healing of diabetic foot are related to long-term hyperglycemia, oxidative stress on the wound, aggravated inflammatory response, lipid peroxidation and angiogenesis disorders. Modern medical research shows that angelica can treat drug-resistant bacterial infections, and the angelica coumarin in angelica dahurica has antibacterial effects; the effective active ingredient of frankincense is boswellic acid, which can reduce inflammation, inhibit cell apoptosis, promote angiogenesis and collagen deposition to accelerate the healing of wounds in diabetic rats; modern pharmacological studies have found that red peony root contains baicalein, β-sitosterol, ellagic acid and other active ingredients, which may exert antioxidant stress effects by regulating key targets in the PI3K-AKT signaling pathway through these active ingredients; scorpion venom active peptides inhibit the expression of IL-6, thereby inhibiting the inflammatory response and promoting granulation tissue and angiogenesis, thereby promoting wound healing. This topical Chinese medicine powder is formulated based on the TCM pathogenesis of diabetic foot ulcers and the pathogenesis of modern medicine, following TCM syndrome differentiation and principle formulation, to effectively delay and treat diabetic foot ulcers. Animal experiments have shown that it can effectively alleviate the inflammatory response in rats with diabetic foot ulcers, promote granulation tissue and angiogenesis in the wound, and accelerate wound healing. Furthermore, the medicinal materials used to prepare this topical Chinese medicine powder are all commonly available, reasonably priced, and simple to prepare, making it suitable for industrial production.

[0015] The technical effects of the present invention will be demonstrated through animal experiments below.

[0016] 1. Pharmacodynamics experiments

[0017] To verify the pharmacological effects of the drug of the present invention in delaying and treating diabetic foot ulcers and provide a scientific basis for its clinical use, the following pharmacodynamic experiments were specifically conducted. In this experiment, a rat model of diabetic foot ulcers was used to detect the wound healing rate, histopathological changes of the wound tissue, and indexes related to inflammation and angiogenesis.

[0018] 1.1 Experimental materials

[0019] 1.1.1 Experimental subjects

[0020] Forty male SPF-grade Sprague-Dawley rats (purchased from Guangdong Provincial Center for Medical Laboratory Animals, animal production license number: SCXK(Yue)2018-0002), weighing 200-300 g.

[0021] 1.1.2 Experimental conditions

[0022] All rats were adaptively fed for 7 days before the experiment, at a constant temperature of 24-26 °C, relative humidity of 40%-60%, with a 12-hour light-dark cycle, and free access to water and food. All rats were housed separately in cages, 5 rats per cage, with free access to water and standard feed for free intake.

[0023] 1.1.3 Main experimental instruments and equipment

[0024] Yuwell blood glucose meter (Jiangsu Yuwell); Epoch microplate reader (BioTeK, USA); ME203E / 02 electronic balance (Mettler Toledo, Shanghai); RT-3100C automatic microplate washer (Leadman, Shenzhen); D3024R desktop high-speed refrigerated centrifuge (Dalong, Beijing); PANNORAMIC panoramic slide scanner (3DHISTECH Hungary).

[0025] 1.1.4 Tested drugs

[0026] Experimental group: Take the powder of the following Example 1 and directly apply it externally on the wound surface, with the drug about 2 mm thick, covering the entire wound surface. Change the dressing once a day.

[0027] 1.2 Experimental methods

[0028] 1.2.1 Experimental grouping

[0029] After purchase, the rats were adaptively fed for 1 week and then randomly divided into a blank control group (n=10) and a diabetic model group (n=30). The control group was fed with ordinary feed, and the model group was fed with a high-fat feed after adaptive feeding for 1 week. After 4 weeks of feeding, the rats were fasted for 12 hours but not water, and given a single intraperitoneal injection of 1% streptozotocin 65 mg / kg. Three days later, blood was collected from the tail vein to measure fasting blood glucose (FBG). FBG ≥ 16.7 mmol / L was considered a sign of successful diabetic model establishment. Finally, 27 rats were successfully modeled with diabetes. After the successful modeling, each rat was given metformin hydrochloride tablets 200 mg / kg.d by gavage to control blood sugar. One rat in the control group died naturally during the breeding process. The next day after the successful modeling, 36 rats were subjected to foot ulcer modeling. The rats were anesthetized by intraperitoneal injection of 3% sodium pentobarbital and the dorsum of the feet was disinfected. They were then scalded with 80℃ hot water to form blisters, and ulcer surfaces formed after 24 hours. During the foot modeling process, one rat in the control group died and three rats in the diabetic group died. Finally, a total of 32 rats were successfully modeled and randomly divided into control group, model group, positive control group and experimental group, with 8 rats in each group.

[0030] Control group: Iodine-containing disinfection and dressing change were given once a day starting from the first day after ulcer formation.

[0031] Model group: Iodine disinfection and dressing change were given once a day starting from the first day after ulcer formation.

[0032] Positive control group: iodine disinfection and povidone cream dressing were given once a day starting from the first day after ulcer formation.

[0033] Experimental group: The powder of Example 1 below was administered daily as a dressing change starting from the first day after ulcer formation, once a day.

[0034] 1.2.3 Observation indicators

[0035] The general condition of the rats, fasting blood glucose, wound healing rate, pathological changes of wound tissue by HE staining, serum inflammatory factors interleukin IL-6 and IL-1β, protein expression level of vascular endothelial growth factor (VEGF) in the wound, and protein expression and mRNA levels of PI3K, AKT, Relaxin, and Apelin in the wound tissue were measured.

[0036] 1.2.4 Data Statistics

[0037] SPSS 24.0 software was used for statistical analysis. All experimental data were measured data, and the measured data were expressed as mean ± standard deviation. The data were compared between groups using one-way analysis of variance. Statistically significant differences were further compared between groups using the LSD-t method. P < 0.05 was considered statistically significant.

[0038] 1.3 Results

[0039] 1.3.1 General condition of rats

[0040] The rats in the normal control group were quiet, lively and active, with smooth and neat fur, bright eyes, sensitive to food, quick escape reaction, slightly red and swollen wound surface, thin secretions and small ulcer area.

[0041] After the diabetic model was established, rats showed symptoms such as polydipsia, polyphagia, polyuria, weight loss, lack of activity, mental depression, slow reaction, hair loss, dullness, redness and swelling of the wound surface, increased secretions, and larger ulcer area.

[0042] After the modeling was completed, the drug group of the present invention began to be treated with external application of the drug. Compared with the model group and the positive control group, the depressed state of the rats was improved.

[0043] 1.3.2 Changes in fasting blood glucose levels in rats

[0044] After modeling, the fasting blood glucose levels of rats in both the model and experimental groups were higher than those in the control group (P < 0.05), indicating that the diabetic rat model was successfully established and that pancreatic islet function was damaged, leading to elevated blood glucose levels in the rats. At 7, 14, and 28 days after drug intervention, no significant differences were observed in fasting blood glucose levels between the experimental and model groups, or between the experimental and positive control groups (P > 0.05). This suggests that the drug of the present invention has no significant effect on improving fasting blood glucose in rats.

[0045] Table 1 Comparison of FBG levels in rats of each group (mmol / L,

[0046]

[0047] Note: Compared with the control group, *P<0.05.

[0048] 1.3.3 Changes in wound healing rate in rats

[0049] Wound healing rate = (wound area after modeling - wound area after drug treatment) / wound area after modeling × 100%. A higher wound healing rate indicates better wound healing. The wound healing rate of rats in the control group was higher than that of the other three groups on the 7th day of treatment (P < 0.05). The wound healing rates of rats in the positive control and experimental groups were higher than those in the model group (P < 0.05), and the wound healing rate of rats in the experimental group was lower than that in the positive control group (P < 0.05). On the 28th day of treatment, the wound healing rates of the control, positive control, and experimental groups were significantly higher than those in the model group (P < 0.05), and the wound healing rate of rats in the experimental group was higher than that in the positive control group (P < 0.05). This indicates that the drug of the present invention can effectively promote wound healing in rats with diabetic foot ulcers and shorten the wound healing time.

[0050] Table 2 Comparison of wound healing rates in rats in each group (%,

[0051]

[0052] Note: Compared with the control group, *P < 0.05, compared with the model group, #P < 0.05, compared with the positive control group, +P < 0.05.

[0053] 1.3.4 Changes in serum inflammatory factors IL-6 and IL-1β in rats

[0054] Compared with the control group, the serum levels of IL-6 and IL-1β in rats in the other three groups were elevated (P < 0.05), suggesting that the difficulty in wound healing in rats with diabetic foot ulcers is associated with elevated inflammatory markers. Compared with the model group, the serum levels of IL-6 and IL-1β in rats in the positive control group and experimental group decreased (P < 0.05), and the serum levels of IL-6 and IL-1β in rats in the experimental group were lower than those in the positive control group (P < 0.05). This indicates that the drug of this invention can effectively reduce serum inflammatory factors and alleviate inflammatory responses.

[0055] Table 3 Comparison of serum IL-6 and IL-1β levels in rats of each group (pg / ml,

[0056]

[0057] Note: Compared with the control group, *P < 0.05, compared with the model group, #P < 0.05, compared with the positive control group, +P < 0.05.

[0058] 1.3.5 Comparison of pathological changes in ulcer wounds in rats of different groups

[0059] In the control group, a large amount of new granulation tissue and capillaries were observed in the wound tissue, with only a small amount of inflammatory cell infiltration. In the model group, a large amount of inflammatory cell infiltration was observed in the wound tissue, and both granulation tissue and new capillaries were significantly reduced. In the positive control group and experimental group, inflammatory cell infiltration in the wound tissue was significantly reduced compared with the model group, while granulation tissue and new capillaries were significantly increased compared with the model group, with the most significant change in the experimental group. This shows that the drug of the present invention can reduce inflammatory cell infiltration in rat wounds and promote the formation of granulation tissue and new capillaries.

[0060] 1.3.6 Changes in PI3K, AKT, and VEGF protein expression in wound tissue

[0061] The WB method was used to detect the protein contents of PI3K, AKT and VEGF in the wound tissues of the rats in each group. Compared with the control group, the expression of AKT in the wounds of the rats in the positive control group and the experimental group was increased (P < 0.05); compared with the model group, the expression of AKT in the wounds of the rats in the positive control group and the experimental group was increased in turn (P < 0.05); and the expression of AKT in the wounds of the rats in the experimental group was higher than that in the positive control group (P < 0.05); compared with the control group, the expression of PI3K in the wounds of the rats in the other three groups was increased (P < 0.05); compared with the model group, the expression of PI3K in the wounds of the rats in the positive control group and the experimental group was increased in turn (P < 0.05); and the expression of PI3K in the wounds of the rats in the experimental group was higher than that in the positive control group (P < 0.05). Compared with the control group, the expression of VEGF in the wounds of rats in the model group and the positive control group decreased (P < 0.05); compared with the model group, the expression of VEGF in the wounds of rats in the positive control group and the experimental group increased in that order (P < 0.05); and the expression of VEGF in the wounds of rats in the experimental group was higher than that in the positive control group (P < 0.05). This suggests that the drug of the present invention can promote the increase of VEGF in the wound surface, accelerate the formation of new blood vessels in the wound surface, and promote wound healing.

[0062] Table 4 Comparison of PI3K, AKT and VEGF protein expressions in the wounds of rats in each group

[0063]

[0064] Note: Compared with the control group, *P < 0.05, compared with the model group, #P < 0.05, compared with the positive control group, +P < 0.05.

[0065] 1.3.7 Changes in Relaxin and Apelin Protein Expression in Wound Tissue

[0066] ELISA was used to detect the protein levels of Relaxin and Apelin in the wound tissues of the rats in each group. Compared with the control group, the expression of Apelin in the wounds of the rats in the remaining three groups was increased (P < 0.05). Compared with the model group, the expression of Apelin in the wounds of the rats in the positive control group and the experimental group was increased in that order (P < 0.05), and the expression of Apelin in the wounds of the rats in the experimental group was higher than that in the positive control group (P < 0.05). Compared with the control group, the expression of Relaxin in the wounds of the rats in the remaining three groups was decreased (P < 0.05). Compared with the model group, the expression of Relaxin in the wounds of the rats in the positive control group and the experimental group was increased in that order (P < 0.05), and the expression of Relaxin in the wounds of the rats in the experimental group was higher than that in the positive control group (P < 0.05).

[0067] Table 5 Comparison of Relaxin and Apelin protein expressions in the wounds of rats in each group (ng / ml, pg / ml,

[0068]

[0069] Note: Compared with the control group, *P < 0.05, compared with the model group, #P < 0.05, compared with the positive control group, +P < 0.05.

[0070] 1.3.8 Changes in Relaxin, Apelin, AKT, and PI3K mRNA Expression in Wound Tissue

[0071] The mRNA levels of Relaxin, Apelin, AKT and PI3K in wound tissues were detected by qPCR. The expression of Relaxin mRNA in the wounds of rats in the model group, positive control group, and experimental group was lower than that in the control group (P < 0.05), while the expression of Apelin mRNA in the wounds was higher than that in the control group (P < 0.05). Compared with the model group, the expression of Relaxin and Apelin mRNA in the wounds of rats in the positive control group and experimental group increased in that order (P < 0.05). Moreover, the expression of Relaxin and Apelin mRNA in the wounds of rats in the experimental group was higher than that in the positive control group (P < 0.05). The expression of AKT mRNA in the wounds of rats in the positive control group and experimental group was higher than that in the control group (P < 0.05). There was no significant difference in the expression of AKT mRNA in the wounds of rats in the model group and the control group (P > 0.05). The expression of PI3K mRNA in the wounds of rats in the model group, positive control group, and experimental group was higher than that in the control group (P < 0.05). Compared with the model group, the expression of AKT and PI3K mRNA in the wounds of rats in the positive control group and experimental group increased (P < 0.05). The mRNA expression level was higher than that of the positive control group (P < 0.05). The PI3K / AKT signaling pathway plays a key role in inflammation and angiogenesis. PI3K activates the PI3K / AKT pathway, which can further activate AKT under the stimulation of growth factors, promote the proliferation and migration of endothelial cells and fibroblasts, and then generate new microvessels, thereby promoting wound healing. Apelin can inhibit diabetes, high glucose and elevated inflammatory factors by upregulating human deacetylase 1 (HDAC1). Relaxin can accelerate angiogenesis by stimulating vascular endothelial growth factor (VEGF) and stromal cell-derived factor (SDF) 1-α, selectively target angiogenesis at the wound site, and regulate metalloproteinase (MMP) expression to prevent fibrosis in mice, thereby promoting diabetic wound healing. The drug of the present invention promotes the healing of diabetic foot ulcer wounds by activating the PI3K-AKT / Relaxin / Apelin signaling pathway.

[0072] Table 6 Comparison of Relaxin, Apelin, AKT and PI3K mRNA expressions in the wounds of rats in each group

[0073]

[0074] Note: Compared with the control group, *P < 0.05, compared with the model group, #P < 0.05, compared with the positive control group, +P < 0.05.

[0075] 1.4 Conclusion

[0076] Through comprehensive research on multiple indicators of drug intervention in the rat DFU model, this experiment verified that this external Chinese medicine powder can reduce the inflammatory response of rats, promote the formation of granulation tissue and new blood vessels in the wound, accelerate wound healing, and effectively treat diabetic foot ulcers. BRIEF DESCRIPTION OF THE DRAWINGS

[0077] Figure 1 HE staining micrographs of the wound tissue pathological changes in rats in each group (HE staining, ×200).

[0078] Figure 2 The electrophoresis diagrams of PI3K, AKT, VEGF, and β-actin in the wound surfaces of rats in each group are shown. In the figure, A is the experimental group, B is the positive control group, C is the control group, and D is the model group. DETAILED DESCRIPTION

[0079] Example 1: (Powder)

[0080] Prescription: 24g of whole scorpion, 24g of angelica, 24g of white peony root, 24g of red peony root, 15g of rhubarb, 15g of angelica dahurica, 15g of frankincense, 15g of myrrh, 15g of catechu, and 15g of dragon's blood.

[0081] Preparation method: Take the raw materials according to the above ratio, grind them, pass through a 120-mesh sieve, and prepare them into powder.

[0082] Usage: Apply externally to cover the wound and bandage with sterile gauze. The thickness of the medicine should be about 2mm, covering the entire wound surface. Change the dressing once a day.

[0083] Example 2: (Powder)

[0084] Prescription: 22g of whole scorpion, 22g of angelica, 22g of white peony root, 24g of red peony root, 15g of rhubarb, 16g of angelica dahurica, 15g of frankincense, 16g of myrrh, 15g of catechu, and 15g of dragon's blood.

[0085] Preparation method: same as Example 1.

[0086] Usage: Same as Example 1.

[0087] Example 3: (Powder)

[0088] Prescription: 25g of whole scorpion, 25g of angelica, 25g of white peony root, 23g of red peony root, 14g of rhubarb, 14g of angelica dahurica, 14g of frankincense, 14g of myrrh, 14g of catechu, and 14g of dragon's blood.

[0089] Preparation method: same as Example 1.

[0090] Usage: Same as Example 1.

Claims

1. A Chinese medicinal powder for external use for treating diabetic foot ulcers, characterized in that This Chinese medicine powder for external use is made from the following raw materials in percentage by weight: Scorpion 12-14%, Chinese angelica 12-14%, white mulberry 12-14%, red peony root 12-14%, rhubarb 7-9%, white angelica 7-9%, frankincense 7-9%, myrrh 7-9%, catechu 7-9%, dragon's blood 7-9%.

2. The external-use Chinese medicinal powder for treating diabetic foot ulcer according to claim 1, characterized in that: The traditional Chinese medicine powder is prepared from the following raw materials in percentage by weight: 13% of scorpion, 13% of angelica, 13% of white peony root, 13% of red peony root, 8% of rhubarb, 8% of angelica dahurica, 8% of frankincense, 8% of myrrh, 8% of catechu, and 8% of dragon's blood.

3. The external-use Chinese medicinal powder for treating diabetic foot ulcer according to claim 1 or 2, characterized in that: The external-use Chinese medicine powder is prepared by the following method: The raw materials are ground according to the ratio, passed through a 120-mesh sieve, and prepared into the external Chinese medicine powder.

Images